Pharmaceutical Executive-09-01-2019

Pharm Exec’s latest analysis of financial performance reveals that it’s those drugmakers maximizing the difference between the value and the cost of their capital investments that are delivering the most bang for the buck to shareholders.

Reoccurring disappointment in development portfolios-why it happens and how to mitigate it.

Expedited reviews drive new imperative for iteration and quality data that enable agility and results.

There are many factors involved in launching a drug but one prevailing goal: brand awareness. I caught up with Fingerpaint's Bryan O’Malley, who shared some of today's key digital trends affecting that mission.

Tech-driven changes to training and learning systems-and how brand information is provided and shared-are overhauling approaches to sales rep preparation.

Market consolidation limits sales, while legal challenges offset regulatory gains.

Following a new product’s first year on the market, there are four key ways companies can refine commercial strategies to maximize product sales.

Pharm Exec’s annual feature profiling a selection of notable biopharma brands focuses this year on new beginnings and new promise-spotlighting five products with compelling product launch stories that tie strongly with the industry’s broader and evolving market-entry landscape.

The key ingredients for biopharma startups in building their brand story.

Click the title above to open the Pharmaceutical Executive September 2019 issue in an interactive PDF format.

A decade into China’s far-reaching healthcare reforms-which began with the implementation of universal, albeit rudimentary, medical insurance-the pace of change and transformation within the country’s life sciences industry shows no signs of abating.

Amid the noteworthy product launches profiled this year by Pharm Exec are four more therapy trailblazers worth highlighting.